IL6 and neoplasm: As for predictive biomarkers of resistance, emerging data highlight factors such as PTEN loss or PI3K pathway activation in tumors (which can exclude T cells) and certain cytokines (elevated IL-6 or IL-8), as markers of an immune-cold tumor.